GSK706769/KALETRA Drug-drug Interaction Study

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636 ·Status: COMPLETED ·Phase: PHASE2

Kaletra in Combination With Antiretroviral Agents

NCT01076179 ·Status: COMPLETED

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

NCT00234975 ·Status: COMPLETED ·Phase: PHASE4

Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra

NCT00176033 ·Status: COMPLETED

Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin

NCT01057433 ·Status: COMPLETED ·Phase: PHASE4

Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil

NCT00474201 ·Status: COMPLETED ·Phase: NA

Special Investigation of Kaletra in Pregnant Women

NCT01076985 ·Status: COMPLETED

Lopinavir/Ritonavir (Kaletra) PK in Children

NCT00810108 ·Status: COMPLETED ·Phase: PHASE4

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

NCT01153269 ·Status: COMPLETED

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

NCT00833378 ·Status: COMPLETED ·Phase: PHASE1

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

NCT00247143 ·Status: UNKNOWN ·Phase: NA

Dose Reduction of Lopinavir in Children

NCT00887120 ·Status: COMPLETED ·Phase: PHASE2

The Effect of Lopinavir/Ritonavir on Endothelial Function

NCT00076414 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients

NCT00234923 ·Status: COMPLETED ·Phase: PHASE3

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

NCT00025727 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation

NCT04138199 ·Status: TERMINATED

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

NCT01101893 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.

NCT00985543 ·Status: COMPLETED ·Phase: PHASE1

Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women

NCT00102986 ·Status: COMPLETED ·Phase: NA

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926 ·Status: TERMINATED ·Phase: PHASE4

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

NCT00273273 ·Status: COMPLETED

Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use

NCT01379703 ·Status: COMPLETED

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

NCT00867152 ·Status: COMPLETED ·Phase: PHASE1

Surveillance of Kaletra in Korean Patients

NCT01083173 ·Status: COMPLETED